At a glance
ClinicalIndex Comparison RecordN/ACompleted· 812 enrolled
Drug / intervention
ABSORB BVSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ABSORB EXTEND Clinical Investigation: A Continuation in the Clinical Evaluation of the ABSORB Bioresorbable Vascular Scaffold (BVS) System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
In Brief
A clinical study evaluating ABSORB BVS for Myocardial Ischemia and 5 related conditions. Completed, enrolled 812 participants across 56 sites in 25 countries.
Detailed Summary
The ABSORB EXTEND trial is to continue the assessment of the safety and performance of the ABSORB Bioresorbable Vascular Scaffold (BVS) System ABSORB BVS is currently in development at Abbott Vascular.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis, Cardiovascular Disease
CountriesArgentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, India, Israel, Italy, Japan, Malaysia, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartJan 2010
Primary CompletionOct 2016
TodayJul 2026
First PostedDec 2, 2009
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 16.6 years ago
Interventions
ABSORB BVSdevice
Absorb Bioresorbable Vascular Scaffold (BVS) System implantation